Shanghai Yizhong Pharmaceutical Co., Ltd. (SHA:688091)

Market Cap	10.59B +43.7%
Revenue (ttm)	317.08M +82.7%
Net Income	64.13M +819.4%
EPS	0.31 +933.3%
Shares Out	205.43M
PE Ratio	166.29
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,894,572
Average Volume	4,608,445
Open	53.69
Previous Close	53.31
Day's Range	51.27 - 54.05
52-Week Range	33.34 - 83.60
Beta	-0.33
RSI	50.89
Earnings Date	Apr 28, 2026

About SHA:688091

Shanghai Yizhong Pharmaceutical Co., Ltd. engages in the development of anti-tumor drugs and related products in China. It also offers paclitaxel polymer nanomicelles for the treatment of non-small cell lung cancer, as well as various types of cancer, including esophageal cancer, gastric cancer, nasopharyngeal carcinoma, pancreatic cancer, breast cancer, gynecological tumors, etc. The company was founded in 2009 and is headquartered in Shanghai, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2009
• Employees: 415
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688091

Financial Performance

In 2025, SHA:688091's revenue was 317.08 million, an increase of 82.72% compared to the previous year's 173.53 million. Earnings were 64.13 million, an increase of 819.42%.